Table 3.
T2W–, ADC–, DCE–, 3D MRS– | T2W–, ADC+, DCE–, 3D MRS– | T2W+, ADC–, DCE–, 3D MRS– | T2W+, ADC+, DCE–, 3D MRS– | T2W–, ADC+, DCE+, 3D MRS– | T2W+, ADC+, DCE+, 3D MRS– | T2W+, ADC+, DCE+, 3D MRS+ | Total | |
---|---|---|---|---|---|---|---|---|
PIN | – | – | – | 1 | 1 | 1 | – | 3 |
Gleason 6 | 13 | 1 | 1 | 3 | – | 2 | 1 | 21 |
Gleason 7 | 9 | – | – | 4 | – | 4 | 2 | 19 |
Gleason 8 | – | – | – | 1 | – | – | 10 | 11 |
Gleason 9 | – | – | – | – | – | – | 2 | 2 |
Total | 22 | 1 | 1 | 9 | 1 | 7 | 15 | 56 |
PIN, prostatic intraepithelial neoplasia.